Inclusion Criteria : 
  1.  Clinical diagnosis of post herpetic neuralgia , with pain persisting for at least 3 months after the onset of herpes zoster rash OR
  2.  Clinical diagnosis of distal painful polyneuropathy due to Type I or Type II diabetes mellitus with : 
       1.  symmetrical , bilateral pain in the lower extremities for at least 3 months and
       2.  diabetes under control for at least 3 months prior to randomisation , as indicated by a glycated haemoglobin level ( HbA1c ) of â‰¤ 11 % ( 97 mmol / mol ) and on a stable dose of insulin or oral diabetic medication for 3 months prior to screening , and
       3.  no change in diabetic medication planned for the duration of the study
  3.  Positive sensory symptoms ( mechanical or thermal ) associated with neuropathic pain , confirmed by : 
       1.  painDETECT questionnaire ( PD - Q ) and
       2.  Clinical assessment , showing signs of neuropathic pain in either a dermatomal ( PHN ) or distal symmetrical distribution ( DPN ) 
8.  An average daily pain score on the NPRS of at least 4 and no more than 8 in the last five diary entries before randomisation
Exclusion Criteria : 
  1.  Presence of moderate to severe pain from other causes that may confound assessment or self - evaluation of NP . 
  2.  Subjects with both DPN and PHN
